Syros Pharmaceuticals (SYRS) Competitors $0.04 +0.01 (+14.29%) As of 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SYRS vs. GLMD, REVB, QLGN, AWH, PBM, EVAX, SCNI, TNFA, PRFX, and VAXXShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Galmed Pharmaceuticals (GLMD), Revelation Biosciences (REVB), Qualigen Therapeutics (QLGN), Aspira Women's Health (AWH), Psyence Biomedical (PBM), Evaxion Biotech A/S (EVAX), Scinai Immunotherapeutics (SCNI), TNF Pharmaceuticals (TNFA), PainReform (PRFX), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. Galmed Pharmaceuticals Revelation Biosciences Qualigen Therapeutics Aspira Women's Health Psyence Biomedical Evaxion Biotech A/S Scinai Immunotherapeutics TNF Pharmaceuticals PainReform Vaxxinity Syros Pharmaceuticals (NASDAQ:SYRS) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Which has more risk & volatility, SYRS or GLMD? Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Is SYRS or GLMD more profitable? Galmed Pharmaceuticals' return on equity of -28.75% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syros PharmaceuticalsN/A -3,369.56% -97.04% Galmed Pharmaceuticals N/A -28.75%-24.98% Does the media prefer SYRS or GLMD? In the previous week, Galmed Pharmaceuticals had 4 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 5 mentions for Galmed Pharmaceuticals and 1 mentions for Syros Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.18 beat Syros Pharmaceuticals' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syros Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galmed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in SYRS or GLMD? Galmed Pharmaceuticals received 75 more outperform votes than Syros Pharmaceuticals when rated by MarketBeat users. Likewise, 62.52% of users gave Galmed Pharmaceuticals an outperform vote while only 61.27% of users gave Syros Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSyros PharmaceuticalsOutperform Votes36761.27% Underperform Votes23238.73% Galmed PharmaceuticalsOutperform Votes44262.52% Underperform Votes26537.48% Which has higher valuation & earnings, SYRS or GLMD? Galmed Pharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyros Pharmaceuticals$386K2.43-$164.57M-$3.03-0.01Galmed PharmaceuticalsN/AN/A-$6.91M-$16.66-0.07 Do analysts recommend SYRS or GLMD? Syros Pharmaceuticals currently has a consensus target price of $3.33, suggesting a potential upside of 9,451.10%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Syros Pharmaceuticals is more favorable than Galmed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders believe in SYRS or GLMD? 91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummarySyros Pharmaceuticals and Galmed Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$936,000.00$6.83B$5.54B$8.03BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-0.017.4722.7118.78Price / Sales2.43261.15407.35107.90Price / CashN/A65.8538.1834.62Price / Book0.046.616.804.34Net Income-$164.57M$143.37M$3.22B$247.93M7 Day PerformanceN/A3.67%2.16%2.60%1 Month PerformanceN/A6.03%3.54%4.15%1 Year PerformanceN/A-2.39%16.80%5.82% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals2.1298 of 5 stars$0.04+14.3%$3.33+8,233.3%-99.4%$1.07M$386,000.00-0.01120Analyst ForecastNews CoverageGap DownGLMDGalmed Pharmaceuticals0.9486 of 5 stars$1.67+6.4%N/A-72.4%$2.76MN/A-0.1020Analyst ForecastShort Interest ↑High Trading VolumeREVBRevelation Biosciences0.4641 of 5 stars$2.91-0.5%N/A-91.2%$2.63MN/A-0.0110Upcoming EarningsQLGNQualigen TherapeuticsN/A$3.51+0.9%N/A-75.9%$2.58M$4.98M0.0050News CoveragePositive NewsGap DownAWHAspira Women's Health2.3526 of 5 stars$0.08-12.5%$5.50+6,607.3%-97.5%$2.44M$9.18M-0.07110High Trading VolumePBMPsyence BiomedicalN/A$0.53-3.0%N/A-99.5%$2.41MN/A0.00N/APositive NewsEVAXEvaxion Biotech A/S2.7858 of 5 stars$1.65flat$10.00+506.1%-92.0%$2.32M$3.34M-1.1460Short Interest ↓Positive NewsSCNIScinai Immunotherapeutics1.4485 of 5 stars$2.46-2.2%N/A-35.7%$2.29M$452,000.00-0.0120News CoveragePositive NewsGap UpTNFATNF PharmaceuticalsN/A$0.22+1.3%N/AN/A$2.26MN/A-0.026High Trading VolumePRFXPainReform1.8665 of 5 stars$2.32-1.3%$8.00+244.8%-39.1%$2.03MN/A-0.024Gap DownVAXXVaxxinityN/A$0.02+7,400.0%N/A-87.8%$1.90MN/A-0.0390Gap Down Related Companies and Tools Related Companies GLMD Alternatives REVB Alternatives QLGN Alternatives AWH Alternatives PBM Alternatives EVAX Alternatives SCNI Alternatives TNFA Alternatives PRFX Alternatives VAXX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SYRS Stock Free SYRS Stock Alerts